Edesa Biotech opened lower at $2.12, compared with its previous close of $2.22. In the last trading session, the stock traded between $1.99 and $2.35. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Edesa Biotech is now worth
$ 4.22
Resulting in a loss of
$ 95.78 (95.78%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.14 (-6.31%)
Day High
$2.35
Day Low
$1.99
Day Open
$2.12
Prev Close
$2.22
Volume
5,01,229
1W Return
-5.45%
1M Return
-28.67%
3M Return
-62.80%
6M Return
-86.39%
1Y Return
14.29%
Fundamentals
Market Cap ($ Mn)
28
PE Ratio
-
PB Ratio
111.31
PEG Ratio
-
ROE
-202.76%
ROCE
-77.50%
EPS (TTM)
$-0.56
Investment Returns
1 Week
-5.45%
1 Month
-28.67%
3 Months
-62.80%
6 Months
-86.39%
9 Months
94.39%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
9Nov
Edesa Biotech signs $140M Japan deal with Kyorin for paridiprubart
Edesa Biotech secures exclusive license deal with Kyorin for paridiprubart in Japan. Deal includes $12M upfront and up to $134M in milestones, totaling over $140M. Kyorin funds all development and commercialization costs for ARDS treatment in Japan. Paridiprubart showed 39% adjusted mortality risk vs 52% placebo in Phase 3 study.
3 days ago
15Oct
Edesa Biotech secures FDA IND clearance for Phase 2 vitiligo study
FDA cleared IND application for Phase 2 EB06 study in vitiligo. Expansion of recruitment to U.S. investigational sites approved. Topline data anticipated in Q4 2027. Study evaluates EB06 in up to 80 adults with moderate-to-severe vitiligo.
28 days ago
20Aug
Edesa Biotech stock falls 13% after pricing $25 million share offering
Edesa Biotech priced a $25.0 million equity offering comprising common shares and pre-funded warrants, with Guggenheim Securities as manager. The news weighed on the stock, which fell nearly 13% in premarket trading on Thursday, extending losses from an 18.27% drop in Wednesday's after-hours session. Proceeds will fund R&D, manufacturing, and general corporate purposes.
2mo ago
14Aug
Edesa Biotech Q3 loss widens 140% to $5.4M on rising R&D spend
Edesa Biotech's Q3FY26 results show a net loss of $5.4 million, driven by a 344% YoY rise in R&D costs to $4.0 million as it prepares for its Phase 2 vitiligo trial. The company missed EPS estimates, reporting $(0.60) vs $(0.58). Cash reserves remain at $10.3 million.
3mo ago
11Jun
Edesa Biotech raises $3.5 million in private placement led by CEO
Edesa Biotech, Inc. has secured $3.5 million in gross proceeds through a PIPE financing led by its CEO and healthcare investors. The transaction involves the sale of 729,241 common shares at $4.69 per share for investors and $5.21 per share for the CEO, with an expected closing date of June 15, 2026. Proceeds will fund the company's vitiligo program, paridiprubart, and general corporate purposes.
